Publications

Salvage Ablative Radiotherapy for Isolated Local Recurrence of Pancreatic Adenocarcinoma following Definitive Surgery

Dee EC, Ng VC, O'Reilly EM, Wei AC, Lobaugh SM, Varghese AM, Zinovoy M, Romesser PB, et al.

Salvage hepatic artery infusion chemotherapy after first-line systemic failure in patients with unresectable cholangiocarcinoma.

N Nasar, M Armstrong, JF Chou, M Gonen, K Soares, VP Balachandran, ...

Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.

CA O'Connor, E Harrold, YT Lin, HS Walch, A Gazzo, SR Kane, F Keane, ...

SWI/SNF Complex-Deficient Undifferentiated Carcinoma of the Pancreas: Clinicopathologic and Genomic Analysis

Yavas A, Ozcan K, Adsay NV, Balci S, Tarcan ZC, Hechtman JF, Luchini C, Scarpa A, et al.

Updated safety and efficacy from a Phase 1 study of RMC-6236, a RAS (ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC)

B Wolpin, DS Hong, A Spira, A Starodub, W Park, D Sommerhalder, ...

115 Comprehensive spatial, transcriptomic, and genomic analysis of immunogenic biliary tract cancer

W Park, F Keane, HS Ozkan, A Richards, V Rudneva, D Khalil, K Soares, ...

A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.

R Tuli, F Keane, JD Schoenfeld, C O'Connor, C White, JF Chou, ...

A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).

F Keane, JD Schoenfeld, F Crowley, CA O'Connor, C White, C Schwartz, ...

A single cell landscape of malignant pancreas cancer ascites

S Umeda, ER Karnoub, E Ziv, J Wu, C Cruz, W Park, F Balogun, ...

Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).

F Keane, F Balogun, C O'Connor, F Crowley, A Chan, D Cowzer, JF Chou, ...

Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.

D Cowzer, R Huq, M Perry, F Keane, W Park, IH El Dika, D Khalil, J Shia, ...

Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC).

F Keane, L Saadat, C O'Connor, JF Chou, AR Brannon, D Cowzer, ...

Dramatic, durable response to therapy in gBRCA2-mutated pancreas neuroendocrine carcinoma: opportunity and challenge

Keane F, Bajwa R, Selenica P, Park W, Roehrl MH, Reis-Filho JS, Mandelker D, O'Reilly EM

Durable Response after Olaparib Treatment for Perihilar Cholangiocarcinoma with Germline BRCA2 Mutation

Costa BA, Tallón de Lara P, Park W, Keane F, Harding JJ, Khalil DN

Evaluation of microsatellite instability status, a definitive predictive biomarker for immune checkpoint inhibitors (ICI), in underrepresented minorities (URM) with …

F Balogun, M Altoe, C O'Connor, N Chowdhury, A Cercek, C Lee, ...

Favorable Survival after Definitive Ablative RT in Surgically Resectable Pancreatic Cancer Patients

M Reyngold, E O'Reilly, M Zinovoy, C Hajj, AJ Wu, J Cuaron, ...

Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma

Mandelker D, Marra A, Zheng-Lin B, Selenica P, Blanco-Heredia J, Zhu Y, Gazzo A, Wong D, et al.

KRAS(G12D) inhibition in pancreatic cancer: Fas expression facilitates immune clearance

Yeh C, Park W, Yaeger R

Molecular profiles and single cell analysis identify immunogenic pancreatic ductal adenocarcinoma (iPDAC)

W Park, C O'Connor, S Umeda, R Sharma, Y Zhu, ER Karnoub, ...

Pancreatic Cancer: BRCA Targeted Therapy and Beyond

Keane F, O'Connor CA, Park W, Seufferlein T, O'Reilly EM

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer

Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, Lihm J, … Park W, …

Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination …

W Park, C O'Connor, JF Chou, C Schwartz, AM Varghese, M Larsen, ...

Phase II trial of maximal ablative irradiation because of encasement (MAIBE) for patients with potentially resectable locally advanced pancreatic cancer.

M Reyngold, W Alice, EM O'Reilly, MI D'Angelica, JA Drebin, K Soares, ...

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden

Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, et al.

Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid …

AW Tolcher, W Park, JS Wang, AI Spira, PA Janne, HJ Lee, S Gill, ...

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

W Park, EM O'Reilly, J Furuse, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

1304P Characterizing the clinico-genomic landscape and outcomes of KRAS G12C mutated pancreas cancer

F Keane, W Park, A Varghese, F Balogun, K Yu, I El Dika, D Khalil, ...

508 Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition

D Bortone, A Monette, N Tschernia, A Cogdill, Y Najjar, RF Sweis, ...

Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer

Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, Li D, Park W, et al.

Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer

Yu KH, Park J, Mittal A, Abou-Alfa GK, El Dika I, Epstein AS, Ilson DH, Kelsen DP, et al.

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice

Park W, O'Connor CA, Bandlamudi C, Forman D, Chou JF, Umeda S, Reyngold M, Varghese AM, et al.

Distinct KRAS Mutations are Enriched in Early-Stage Resected Pancreatic Ductal Adenocarcinoma

C McIntyre, A Grimont, V Aveson, K Seier, H Walch, A Pulvirenti, R Gelfer, ...

Homologous Recombination Deficiency in Pancreatic Cancer: Poly (ADP-ribose) Polymerase Inhibition, Checkpoint Inhibition, or a Combination of Both?

Keane F, Park W, O'Reilly EM

Immunogenomic characterization of biliary tract cancers: Biomarker enrichment for benefit to immune checkpoint blockade.

W Park, F Keane, C Bandlamudi, M Donoghue, P Tallón de Lara, ...

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma

Zheng-Lin B, Rainone M, Varghese AM, Yu KH, Park W, Berger M, Mehine M, Chou J, et al.

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of “Second Hit” in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma: B …

B Zheng-Lin, M Rainone, AM Varghese, KH Yu, W Park, M Berger, ...

MITI minimum information guidelines for highly multiplexed tissue images

Schapiro D, Yapp C, Sokolov A, Reynolds SM, Chen YA, Sudar D, Xie Y, …

Optimal tumor metastatic gene programs in pancreatic cancer

A Jimenez-Sanchez, Y Xie, R Sharma, TY Chu, V Liu, W Park, A Hayashi, ...

Precision approaches to pancreatic cancer therapy: what now and what next?

F Keane, W Park, EM O’Reilly

Stereotactic ablative radiation for pancreatic cancer on a 1.5 áTelsa magnetic resonance-linac system

KR Tringale, N Tyagi, PB Romesser, A Wu, EM O'Reilly, AM Varghese, ...

Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system

Tringale KR, Tyagi N, Marsha Reyngold, Romesser PB, Wu A, O'Reilly EM, Varghese AM, Godoy Scripes P, et al.

Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study.

W Park, EM O'Reilly, J Furuse, CP Li, DY Oh, R Garcia-Carbonero, G Roth, ...

A Review of Pancreatic Cancer-Reply

Park W, Chawla A, O'Reilly EM

Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer

Reyngold M, O'Reilly EM, Varghese AM, Fiasconaro M, Zinovoy M, … Park W, …

Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, … Park W, …

Genomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumors

Dunbar A, Bolton KL, Devlin SM, Sanchez-Vega F, Gao J, Mones JV, … Park W, …

Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity

O'Connor CA, Park JS, Kaley T, Kezlarian B, Edelweiss M, Yang TJ, Park W, Reidy D, et al.

Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Jolissaint JS, Reyngold M, Bassmann J, Seier KP, Gönen M, Varghese AM, Yu KH, Park W, et al.

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, et al.

Pancreatic cancer: a review

Park W, Chawla A, O'Reilly EM